Merck to Acquire Oncolytic Immunotherapy Developer Viralytics for $394M – Genetic Engineering & Biotechnology News
Endpoints News |
Merck to Acquire Oncolytic Immunotherapy Developer Viralytics for $394M
Genetic Engineering & Biotechnology News Merck & Co. has agreed to acquire Sydney-based Viralytics for approximately A$502 ($394 million), the companies said today, in a deal that expands the buyer's immuno-oncology pipeline with a mid-stage oncolytic immunotherapy that has already shown … For Latest Combo, Merck Bets $394M on Viralytics, Cancer-Fighting Viruses Merck to buy Australian viral immuno-oncology firm for $394 million Merck to buy virus-based cancer drug firm Viralytics for $394 million |
